 | Up a level |
Day, D.; Starus, A.; Gebski, V.; Simes, J.; Hayes, T.; Padinharakam, S.; Strickland, A.H.; Briscoe, K.; Varma, S.; Barnet, M.; Jackson, C.; Horvath, L.G.; Price, T.J.; Tebbutt, N.; Karki, B.; Diakos, C.I.; Chia, J.; Toh, H.C.; Jones, F.S. and Segelov, Eva (October 2023). 586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. Annals of oncology, 34(Suppl 2), S426-S427. Oxford University Press 10.1016/j.annonc.2023.09.1777
